Maxim Group Upgrades Brainstorm Cell Therapeutics (BCLI) to Buy
Tweet
Share
E-mailGet Alerts BCLI Hot Sheet
Price: $1.17 --0%
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Maxim Group analyst Jason McCarthy upgraded Brainstorm Cell Therapeutics (NASDAQ: BCLI) from Hold to Buy with a price target of $2.00.
For an analyst ratings summary and ratings history on Brainstorm Cell Therapeutics click here. For more ratings news on Brainstorm Cell Therapeutics click here.
Shares of Brainstorm Cell Therapeutics closed at $0.35 yesterday.
You May Also Be Interested In
- BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
- RBC Capital Upgrades LTC Properties (LTC) to Outperform
- Cantor Fitzgerald Upgrades Capricor Therapeutics (CAPR) to Overweight
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
